Abstract
Purpose:
Lung adenocarcinoma (LUAD) is the most common type of cancer and the leading cause of cancer-related death worldwide, resulting in a huge economic and social burden. MiRNA-195-5p plays crucial roles in the initiation and progression of cancer. However, the significance of the miRNA-195-5p/polypyrimidine tract-binding protein 1 (miRNA-195-5p/PTBP1) axis in the progression of lung adenocarcinoma (LUAD) remains unclear.
Methods:
Data were collected from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The starBase database was employed to examine the expression of miRNA-195-5p, while the Kaplan–Meier plotter, UALCAN, and Gene Expression Profiling Interactive Analysis (GEPIA) databases were utilized to analyze the tumor stage and prognostic value of miRNA and PTBP1. Quantitative reverse transcription-polymerase chain reaction assay was conducted to detect the expression levels of miRNA-195-5p in LUAD cell lines and tissues. The effects of miRNA-195-5p on cell proliferation and migration were examined using the cell growth curve, clone information, transwell assays, and wound healing assays.
Results:
We found that miRNA-195-5p was down-regulated in LUAD cancer and cell lines. Importantly, its low levels were related to the tumor stage, lymph node metastasis, and poor prognosis in LUAD. Overexpression of miR-195-5p significantly inhibited cell growth and migration promotes cell apoptosis. Further study revealed that PTBP1 is a target gene of miRNA-195-5p, and overexpression of miRNA-195-5p inhibited the progression of LUAD by inhibiting PTBP1 expression. MiRNA-195-5p expression was related to immune infiltration in lung adenocarcinoma. Moreover, PTBP1 was negatively correlated with diverse immune cell infiltration and drug sensitivity.
Conclusion:
Our findings uncover a pivotal mechanism that miRNA-195-5p by modulate PTBP1 expression to inhibit the progression of LUAD. MiRNA-195-5p could be a novel diagnostic and prognostic molecular marker for LUAD.
Introduction
Lung cancer is one of the most common types of cancer and one of the leading causes of cancer-related death worldwide (1). It mainly includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC); the latter comprises adenocarcinoma (LUAD), squamous cell carcinoma (LUSC), and large-cell carcinoma (LCLC) (2, 3). In recent years, numerous advances in the diagnosis and treatment of LUAD have been achieved. Nevertheless, the incidence and mortality rates of lung cancer remain very high. Therefore, the development of novel therapeutic strategies to improve patient survival time with lung cancer is urgently warranted.
MicroRNAs (miRNAs) are endogenously expressed ncRNAs with important biological function as a posttranscriptional gene regulator (4). Emerging evidence has demonstrated that miRNAs plays crucial roles in cancer initiation, progression, metastasis, and response to therapy (5). MiR-212-3p, miR-27a-3p and miR-132-5p are significantly upregulated in LUAD adenocarcinoma (6). miR-197-5p, miR-93-5p, miR-378a-3p and miR-98-5p downregulate the expression of FUS1/TUSC2, another tumor suppressor gene located on Chr.3p21.3 (7). It has been reported that miR-195-5p is a key regulator in multiple types of cancer [e.g., gastric (8), colorectal (9), cervical (10), prostate (11), and pancreatic (12)]. For instance, it has been confirmed that miR-195-5p modulates the polarization of M2-like tumor-associated macrophages and inhibits the progression of colorectal cancer (9). By regulating the expression of Yes1-associated transcriptional regulator (YAP1), miR-195-5p inhibits the malignant progression of cervical cancer (10). Moreover, it regulates the multi−drug resistance of gastric cancer cells by modulating the expression of zinc finger protein 139 (ZNF139) (13). A previous study showed that miR-195-5p may act as a prognostic factor of the diagnosis of lung cancer (14). However, the potential roles of the miRNA-195-5p/polypyrimidine tract-binding protein 1 (miR-195-5p/PTBP1) axis in modulating LUAD progression remain unclear.
PTBP1, as a significant RNA-binding protein, plays indispensable roles in RNA metabolism (15). It is well documented that abnormal PTBP1 expression leads to progression in various types of cancer. For example, it has been shown that PTBP1 modulates pyruvate kinase M1/M2 (PKM1/M2) splicing, thereby inhibiting cancer-specific energy metabolism (16). In bladder cancer, splicing factor PTBP1 elevated the expression of oncogenic splice variants, predicting poor prognosis (17). High expression of PTBP1 regulates the alternative splicing of cortactin and promotes the progression of colorectal cancer (18). Furthermore, a study suggested that PTBP1 plays important role in the maintenance of growth and malignant properties of breast cancer cells (18). Another crucial function of PTBP1 is its participation in the internal ribosome entry site-mediated translation (19). Indeed, it has been reported that PTBP1 may play indispensable roles in the initiation of translation (20). However, there are no studies investigating its prognostic and immunological significance in patients with LUAD, and the upstream modulatory molecular mechanism of PTBP1 involved in LUAD progression remains unknown.
The objective of this study was to investigate the clinical significance and immunological role of the miRNA-195-5p/polypyrimidine tract-binding protein 1 (miRNA-195-5p/PTBP1) axis in the progression of LUAD.
Methods
Data Collection
TCGA-LUAD cohort data and corresponding clinical information of 535 LUAD patients were downloaded from the TCGA website (https://portal.gdc.cancer.gov/repository). The gene expression profiles were normalized using the scale method provided in the “limma” R package. Data analysis was performed with the R (version 3.6.3) and ggplot2 [3.3.3] packages.
Correlation Between PTBP1 Expression, Immune Cell Infiltrates, and Drug Sensitivity
The TIMER (https://cistrome.shinyapps.io/timer/) (21) and TISIDB (http://cis.hku.hk/TISIDB/) (22) databases were using to examined the correlation between the PTBP1 expression and diverse immune cell infiltrates. We employed the CTRP databases (http://portals.broadinstitute.org/ctrp/) to analysis the correlation between PTBP1 expression and drug sensitivity (23, 24).
Predicted and Analysis the Target Gene of miRNA-195-5p
We employed the starbase (http://starbase.sysu.edu.cn/), targetscan (http://www.targetscan.org/)and miRDB (http://mirdb.org/) to Predicted and analysis the target gene of miRNA-195-5p (25, 26). Additionally, we using the starbase to examined the correlation and binding site between the PTBP1, miRNA-195-5p.
Gene Set Enrichment Analysis
We used starbase (https://starbase.sysu.edu.cn/) (27) to obtain the target genes of miRNA-195-5p.
The GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed for the target gene of miRNA-195-5p using the clusterProfiler package (28).
Univariate and Multivariate Cox Regression Analyses
Cox regression analysis, including univariate, and multivariate analyses, was used to examine the prognostic value of miRNA-195-5p and PTBP1 in LUAD. The forest plot was constructed using the R package “forest plot” to exhibit the hazard ratio (HR), 95% CI, and p-value.
Plasmids Construction and Cell Culture
The BEAS-2B cell line was purchased from cell bank of Kunming Institute of Zoology, and cultured in BEGM media (Lonza, CC-3170). Lung cancer cell lines, including A549, H1650 and H1975 were purchased from Cobioer, China with STR document, A549, H1650 and H1975 cells were all cultured in RPMI1640 medium (Corning) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
Quantitative Real-Time PCR
The qRT-PCR assay was performed as documented (29). The primer sequences are list follows: miR-195-5p-F: GAATTCGCCTCAAGAGAACAAAGTGGAG, miR-195-5p R: AGATCTCCCATGGGGGCTCAGCCCCT; U6-F: GGTCGGGCAGGAAAGAGGGC, U6-R: GCTAATCTTCTCTGTATCGTTCC, PTBP1-F: AGCGCGTGAAGATCCTGTTC, PTBP1-R: CAGGGGTGAGTTGCCGTAG, β-actin-F: CTTCGCGGGCGACGAT, β-actin-R: CCATAGGAATCCTTCTGACC. The expression quantification was obtained with the 2−ΔΔCt method.
Cell Proliferation and Migration Assay
For cell proliferation assay, indicated cells were plated into 12-well plates at a density of 1.5×104, the cell numbers were subsequently counted each day using an automatic cell analyzer countstar (Shanghai Ruiyu Biotech Co., China, IC 1000). For colony formation assay, indicated cells were seeded in 6-well plate (China, NEST, Cat. 703001) with 600 cells per well supplemented with 2 mL cell culture medium, and the cell culture medium was changed every 3 days for 2~3 weeks, and then indicated cells were fixed with 4% PFA and stained with 0.5% crystal violet.
Clinical Sample Collection
A total of 15 NSCLC patients tissues and adjacent tissues were collected to perform the qRT-PCR assay to examine the expression of miRNA-195-5p in lung cancer. This study was reviewed and approved by Ethics Committee of The Third Affiliated Hospital of Kunming Medical University. This study complies with the ethics committee regulations and conducted with the informed consent of the patients. Meanwhile, these samples were frozen in liquid nitrogen immediately and stored at −80°C for subsequent experiments. The clinical information in Supplementary Table 5.
Statistical Analysis
Correlation analysis was performed using the Pearson correlation test. The significance of the data between the two experimental groups was determined by Student’s t-test, and multiple group comparisons were analyzed by one-way ANOVA. P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***), were considered significant.
Results
Pan-Cancer Analysis Revealed Low miRNA-195-5p Expression
We employed the TCGA database to examine the expression profile of miRNA-195-5p in various human cancers. The results revealed that miRNA-195-5p was low in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma, liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), stomach adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma (UCEC) (Figure 1A and Supplementary Table 1). In contrast, high expression of miRNA-195-5p was observed in KIRC and prostate adenocarcinoma (Figure 1A). Collectively, these results demonstrated that the expression of miRNA-195-5p is down-regulated in most human cancers.
Figure 1
Next, to evaluate the prognostic value of miRNA-195-5p, we performed overall survival (OS) analysis in various human cancers. The results showed that low expression of miRNA-195-5p was related to good overall survival (OS) in BLCA, KIRC, and ovarian serous cystadenocarcinoma, and associated with poor overall survival in BRCA, LIHC, LUAD, LUSC, sarcoma, and UCEC (Figures 1B–D). These results confirmed that miRNA-195-5p may play different roles in the progression of an array of cancers.
MiRNA-195-5p Expression Was Correlated With the Tumor Stage in Various Cancers
Considering its low expression in human cancer, we further explored the correlation between miRNA-195-5p expression and pathological stage in cancer. The results suggested that miRNA-195-5p expression was significantly related to the pathological stage in KIRC, LUAD, PRAD, and THYM (Figure 2A). In summary, these findings showed that miRNA-195-5p expression was significantly correlated with the pathological stage of various cancers.
Figure 2
Subsequently, we examined whether miRNA-195-5p acts as a detection index for the diagnosis of various cancers. The receiver operating characteristic curve analysis of miRNA-195-5p showed the following area under the curve (AUC) values: 0.910 for BRCA; 0.907 for BLCA; 0.756 for cholangiocarcinoma; 0.985 for colon adenocarcinoma; 0.787 for esophageal carcinoma; 0.930 for head and neck squamous cell carcinoma; 0.954 for kidney chromophobe; 0.607 for KIRC; 0.945 for kidney renal papillary cell carcinoma; 0.920 for LIHC; 0.823 for LUAD; 0.963 for LUSC; 0.879 for LUAD; 0.804 for stomach adenocarcinoma; 0.910 for thyroid carcinoma; and 0.842 for UCEC (Figure 2B). These results indicated that miRNA-195-5p may act as a detection index for the diagnosis of various types of cancer with high sensitivity and specificity.
Analysis of the Function of Target Genes of miRNA-195-5p
Considering that miRNA-195-5p was markedly correlated with the prognosis, tumor stage, and lymph node metastasis, we next investigated the functions of its target genes in various cancers. We utilized the starBase and TargetScan database to identify the potential target genes of miRNA-195-5p. Next, we used these genes to conducted GO and KEGG enrichment analysis. Results confirmed that these genes were mainly involved in signaling pathways, including the mechanistic target of rapamycin kinase (mTOR), autophagy, and insulin signaling pathways. In terms of molecular function, these target genes are mainly involved in small GTPase binding, Ras GTPase binding, cell-substrate junction, and focal adhesion (Figure 3A). The main pathways in which target genes of miRNA-195-5p participate include mTOR signaling, epithelial-mesenchymal transition, and apoptosis (Figure 3B). These findings suggested that the target genes of miRNA-195-5p play pivotal roles in cancer progression.
Figure 3
MiRNA-195-5p Expression Was Down-Regulated in LUAD
The public database revealed that miRNA-195-5p was significantly decreased in LUAD and LUSC (Figures 4A, B); and its low expression correlated with tumor stage and lymph node metastasis (Figures 4C, D). To validate the above results, we analyzed a diverse Gene Expression Omnibus (GEO) dataset and found that miRNA-195-5p was decreased in lung cancer tissue (Figure 4E). To further investigate the expression of miR-195-5p in LUAD, we first detected its levels in 15 pairs of lung cancer samples using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The results indicated that miR-195-5p expression was markedly lower in lung cancer tissues compared with adjacent normal tissues (Figure 4F). Moreover, we used the qRT-PCR assay to examine the expression of miRNA-195-5p in various LUAD cell lines. The data showed that miRNA-195-5p expression was down-regulated in LUAD cells versus normal BEAS-2B cells (Figure 4G). Finally, we found that low expression of miRNA-195-5 was correlated with poor overall survival and disease-specific survival (DSS) in LUAD patients (Figures 4H, I); To further validate the overall survival of miR-195-5p in LUAD patients, we examined the prognosis of miR-195-5p in lung cancer by clinical samples from Yunnan Cancer Hospital (N=181). The results also confirmed that low miR-195-5p expression had a worse OS than the high miR-195-5p expression group (Figure 4J). These results indicated that miRNA-195-5p may act as a detection index for the diagnosis of LUAD with high sensitivity and specificity.
Figure 4
MiRNA-195-5p Is an Independent Prognostic Factor in LUAD
To further examine whether miRNA-195-5p was an independent prognostic factor in LUAD. Univariate Cox regression analysis demonstrated that miRNA-195-5p expression (p = 0.029), pathological stage (p < 0.001), T stage (p < 0.001), M stage (p =0.002), and Residual tumor stage (p < 0.001) were significantly correlated with OS in LUAD (Figure 4K); Multivariate analysis indicated that miRNA-195-5p expression (p = 0.0107), pathological stage (p < 0.001), T stage (p =0.032), and Residual tumor stage (p=0.031) were significantly correlated with OS in LUAD (Figure 4L); These results confirmed that miRNA-195-5p was an independent risk factor for LUAD patients.
Overexpression of miRNA-195-5p Inhibited the Proliferation and Migration of LUAD Cells
Given the low expression of miRNA-195-5p in LUAD tissues, we speculated that it may play a suppressive role in the pathogenesis of this disease. To investigate its functions in LUAD, we transiently overexpressed miRNA-195-5p mimics in A549 cells. The expression levels of miRNA-195-5p after overexpression were detected using qRT-PCR. As expected, the levels of miRNA-195-5p were increased after overexpression of miR-196b-5p (Figure 5A). Furthermore, we conducted the biological function assay to examine the effects of miRNA-195-5p overexpression on the proliferation and migratory ability of NSCLC cells. Results confirmed that overexpression of miRNA-195-5p inhibited the cell growth and cell migration in LUAD, and promoted apoptosis (Figures 5B–E). Collectively, these data imply that miRNA-195-5p plays tumor-suppressive roles in the progression of lung cancer
Figure 5
MiRNA-195-5p Exerted Its Effects by Modulating PTBP1 Expression in LUAD
To decipher the underlying mechanism involved in the function of miRNA-195-5p, we performed bioinformatics analyses for the identification of possible targets. We employed the starBase, TargetScan, and miRDB databases to predict downstream genes. The results indicated that PTBP1, as an important lung cancer stem cell marker gene, may be a target gene of miRNA-195-5p (Figure 6A). The analysis revealed that miRNA-195-5p was negatively correlated with PTBP1 in lung cancer (Figure 6B and Supplementary Table 2). We used the starBase database to examine potential binding sites and analyze the correlation between miRNA-195-5p and PTBP1 (Figure 6C). In addition, we conducted an overexpression analysis to investigate the effects of miRNA-195-5p on the expression of target genes. Forced miRNA-195-5p expression significantly decreased the mRNA levels of PTBP1 in A549 cells (Figure 6D).
Figure 6
The luciferase assay showed that transfection with miR-195-5p mimics significantly reduced the relative luciferase activity of PTBP1-3′-UTR-wild-type-treated lung cancer cells; however, it did not affect that of PTBP1-3′-UTR-mutation-treated lung cancer cells (Figure 6E). Based on the above results, we speculated that miR-195-5p might exert its effects by inhibiting PTBP1 expression. We next overexpressed PTBP1 in A549 cell lines and employed qRT-PCR to validate the efficiency (Figure 6F). Growth curve results confirmed that the overexpression of PTBP1 could reverse the repressed cell proliferation induced by miR-195-5p overexpression in A549 cells (Figure 6G). Transwell and wound healing assays indicated that PTBP1 overexpression abolished the miR-195-5p-caused suppression of migration in A549 cells (Figures 6H, I). Overexpression of miR-195-5p reduced the mRNA levels of PTBP1; these levels were restored following overexpression of PTBP1 (Figure 6J). Taken together, these findings confirmed that miR-195-5p acted as a tumor suppressor by modulating PTBP1 in LUAD.
Correlation Analysis Between miRNA-195-5p Expression and Infiltrating Immune Cells
Considering miRNA-195-5p plays crucial roles in the progression of lung cancer. We examined the correlation between miRNA-195-5p expression and immune infiltration in LUAD by using Spearman correlation, the analysis data demonstrated that miRNA-195-5p positively correlated with the immune infiltration of Mast cells, DC, iDC, NK cells, Macrophages, Th1 cells, B cells, pDC, T cells, TFH, Eosinophils, Cytotoxic cells, CD8 T cells and Neutrophils, negatively correlated with the immune infiltration of NK CD56dim cells and Th2 cells in LUAD (Figures 7A–C). These results demonstrated that miRNA-195-5p plays a significant role in the immune response of LUAD.
Figure 7
PTBP1 Expression Was Upregulated in LUAD
We employed the public database and found that PTBP1 was significantly up-regulated in numerous human cancers, particularly LUAD (Figure 8A). Moreover, its high expression was correlated with tumor stage and poor prognosis (Figures 8B–E). The analysis of GEO datasets yielded consistent results (Supplementary Table 3). To further validate the correlation between PTBP1 expression and overall survival, we examined the prognosis of PTBP1 in lung cancer by clinical samples from Yunnan Cancer Hospital (N=181). The results also showed that higher PTBP1 expression had a worse OS than low PTBP1 expression group (Figure 8F). The AUC value for LUAD was 0.861 (Figure 8G). In addition, higher expression of PTBP1 was correlated with cancer stage (Supplementary Figure 1) and poor prognosis (Supplementary Figure 2). The receiver operating characteristic curve analysis showed that PTBP1 may act as a detection index for the diagnosis of LUAD with high sensitivity and specificity (Supplementary Figure 3). These results demonstrated that PTBP1 plays an important role in tumorigenesis.
Figure 8
PTBP1 is an Independent Prognostic Factor in LUAD
To examine whether PTBP1 was an independent prognostic factor in cancers, Univariate Cox regression analysis demonstrated that PTBP1expression (p < 0.001), pathological stage (p < 0.001), T stage (p < 0.001), N stage (p < 0.001), and M stage (p = 0.006) were significantly correlated with OS in LUAD (Figure 8H); Multivariate analysis indicated that PTBP1 expression (p = 0.011), and T stage (p =0.016) were significantly correlated with OS in LUAD (Figure 8I); These results confirmed that PTBP1 was an independent risk factor for LUAD patients lead to adverse clinical outcomes.
PTBP1 Was Associated With Immune Infiltration in LUAD
We analyzed the expression of PTBP1 in immune subtypes of LUAD. The results demonstrated high expression of PTBP1 mainly in the C4 subtype of LUAD and LUSC (Figure 9A). Next, analysis of the TIMER database revealed that somatic copy number alterations for PTBP1 were significantly correlated with diverse immune cell infiltration levels in LUAD and LUSC (Figures 9B, C). Hence, PTBP1 plays an important role in the immune response, as well as the development and progression of lung cancer. We also explored the correlation between PTBP1 and immune infiltration in LUAD. Results indicated that PTBP1 was positively correlated with the immune infiltration of LUAD tumors by T helper 2 (Th2) cells, natural killer (NK) CD56dim cells, regulatory T NK CD56bright cells, and NK cells. Moreover, it was negatively correlated with immune infiltration by neutrophils, dendritic cells (DC), Th1 cells, Th cells, TcmB cells, T cells, eosinophils, macrophages, interstitial DC, and mast cells (Figure 9D). Our results demonstrated that PTBP1 was positively correlated with the immune infiltration of LUSC tumors by Th2 cells, NK cells, and central memory T cells. Also, it was negatively correlated with immune infiltration by CD8 T cells, Th17 cells, eosinophils, plasmacytoid DC, activated DC, mast cells, cytotoxic cells, T cells, B cells, DC, macrophages, Th1 cells, interstitial DC, and neutrophils (Figure 9E). Collectively, the data indicated that PTBP1 was significantly correlated with immune infiltration in LUAD.
Figure 9
Analysis of the Function of PTBP1 in LUAD
We further explored PTBP1-related signaling pathways involved in the progression of LUAD. For this purpose, we employed LinkedOmics to perform a correlation analysis for PTBP1. The heatmap illustrates the genes which were most positively correlated with PTBP1 (Figure 10A). We next performed KEGG pathway enrichment. The results showed that up-regulation of PTBP1 expression is mainly involved in cell cycle regulation, DNA replication, and base excision repair (Figure 10B). It has been reported that these signaling pathways play important roles in the proliferation of cancer cells.
Figure 10
Gene set enrichment analysis (GSEA) also showed that pathways, including the apoptosis, pathway in cancer, gap junction, focal adhesion, cell cycle, B cell receptor signaling pathway, cytokine-cytokine receptor interaction, chemokine signaling pathway, JAK-STAT signaling pathway, WNT signaling pathway, MAPK signaling pathway, and cell adhesion molecules CAMs, were significantly enriched in the high PTBP1 expression group (Figures 10C–E).
Correlation Between PTBP1 Expression and Tumor Mutational Burden, Microsatellite Instability, and Drug Sensitivity
Emerging evidence has demonstrated that TMB and MSI could be potential biomarkers for predicting the efficacy of immunotherapy for lung cancer (30, 31). The above findings indicated that PTBP1 was significantly correlated with the immune infiltration of tumors. We conducted a correlation analysis to clarify the relationship between PTBP1 expression and TMB, MSI, and drug sensitivity. We found that PTBP1 was also positively correlated with the TMB and MSI in LUAD (Figures 11A, B). For the exploration of potential therapeutic targets, it is extremely important to examine the correlation between PTBP1 expression and various drugs in a pan-cancer analysis. In the present study, we employed the Gene Set Context Analysis tools to analyze the relationship between PTBP1 expression and drug sensitivity. The results demonstrated that PTBP1 expression was negatively correlated with sensitivity to GSK-J4, GSK461364, BRD-K30748066, docetaxel, CD-437, teniposide, chemically modified tetracycline-3 (COL-3), cytarabine hydrochloride, BI-2536, tivantinib, triazolothiadiazine, narciclasine, SB-743921, clofarabine GW-843682X, topotecan, BRD-K70511574, bafilomycin A1, vincristine, decitabine, NVP-231, barasertib, necrosulfonamide, indisulam, PHA-793887, MK-1775, and ceranib-2 (r<−0.30) (Figure 11C and Supplementary Table 4). Taken together, these results suggested that PTBP1 was significantly associated with the sensitivity of different cancer cell lines to various drugs
Figure 11
Discussion
Despite its high incidence and mortality, the exact cause of the development of LUAD is not fully understood. It is well established that LUAD has diverse pathological features. Accumulating evidence suggests that miRNAs play indispensable roles in cancer progression and drug resistance. However, the molecular mechanisms involved in these processes remain unclear. In this study, we analyzed miR-195-5p expression, prognostic value, target genes, and correlation with tumor immune cell infiltration in LUAD for the first time.
The present findings revealed that miRNA-195-5p expression was significantly decreased in various types of cancer, and its low expression was associated with the tumor stage, lymph node metastasis, and unfavorable prognosis of lung cancer. Indeed, it has been confirmed that miR-195-5p was down-regulated in melanoma (32), oral squamous cell carcinoma (33), colon cancer (34), and hepatocellular carcinoma (35). These studies indicated that miR-195-5p plays a fundamental role in malignant suppression, and our results are consistent with these findings.
The high expression of miR-195 can inhibit tumorigenesis and progression and affect the sensitivity of chemotherapeutic agents for malignant tumors, a property that has been applied to drug development. Therefore, it was considered that propofol might induce miR-195 to inhibit the proliferation, migration, and invasion of gastric cancer cells (36). Zuo et al. investigated miR-195 together with long-chain non-coding 00485 (LINC00485) in cisplatin resistance and found that overexpression of miR-195 or silencing of LINC00485 enhances the sensitivity of lung adenocarcinoma cells to cisplatin (37). In this study, we found that miR-195-5p expression was downregulation in LUAD, compared to normal tissues. Moreover, the miR-195-5p expression has associations with tumor pathological stage, lymph node metastasis in LUAD. Meanwhile, the lower miR-195-5p level was related to lymph node metastasis, high tuimor stage. These results suggest that miR-195-5p plays an important role in the progression decreased in some tumor tissues and is associated with clinicopathological features, including late T stage, lymph nodal metastasis, and TNM staging (38, 39). We also found that miRNA-195-5p by inhibited PTBP1 expression lead to inhibition of the prognosis of LUAD.
Results from survival analysis showed that low miR-195-5p expression was associated with poor os, and DSS in LUAD, consistent with previous findings miR-195-5p affects tumor growth and invasion and leads to a poor prognosis (34). Of note, miRNA-195-5p was found to regulate the expression of oncogenes or tumor suppressors and participated in the development of various types of cancer. By targeting mitofusin 2 (MFN2) and F-box and WD repeat domain-containing 7 (FBXW7), miR-195-5p promotes cardiomyocyte hypertrophy (39, 40). It has been reported that miR-195-5p modulates the expression of forkhead box K1 (FOXK1), thereby inhibiting the proliferation of lung cancer cells (41). Notably, circAGFG1 inhibits the expression of miR-195-5p and promotes the progression of triple-negative breast cancer (42). Although some of these findings lack additional experimental verification, our data indicate that miRNA-195-5p may be a promising target and diagnostic or therapeutic biomarker for LUAD. Collectively, these results demonstrated that miRNA-195-5p can be used as a prognostic biomarker for LUAD.
Cancer progression is a complicated process accompanied by increased proliferation, resistance to cell death, enhanced angiogenesis, escape from immune surveillance, and tumor microenvironment (TME) (43). The TME has attracted wide attention in cancer immunotherapy and has been identified as the main contributor to cancer initiation and development (44). Although immunotherapy has made breakthroughs in cancer treatment, it still faces many challenges, and only a limited proportion of cancer patients respond well to immunotherapy. Therefore, the identification of new targets and biomarkers is the key to further improving the efficacy of immunotherapy. Tumor-infiltrating immune cells, including B cells, T cells, dendritic cells, macrophages, and neutrophils, are the major part of the TME (45). Here, to further estimate the relationships between miRNA-195-5p and the TME, we first examined the correlation of miRNA-195-5p expression and the abundance of different infiltrating immune cells across different cancer types. We found that miRNA-195-5p positively correlated with the immune infiltration of Mast cells, DC, iDC, NK cells, Macrophages, Th1 cells, B cells, pDC, T cells, TFH, Eosinophils, Cytotoxic cells, CD8 T cells, and Neutrophils, negatively correlated with the immune infiltration of NK CD56dim cells and Th2 cells in LUAD. These results demonstrated that miRNA-195-5p plays a significant role in the immune response of LUAD.
PTBP1 or polypyrimidine tract binding protein 1 (hnRNPI), is one of the most investigated RBP in vertebrates involved in almost all steps of mRNA regulation during tumorigenesis, due to its RNA-binding activity. PTBP1 is generally described as a widely expressed factor in adult tissues, and accordingly, it is present in most of the cell lines studied (46). The expression levels of PTBP1 have been found to be elevated in brain tumors (47), and different malignant cell lines (48). Furthermore, high expression of PTBP1 has been demonstrated to be associated with the aggressive behavior of several types of cancer, especially in glioma and ovarian tumors (49).
As an important RNA-binding protein, PTBP1 plays a crucial role in RNA metabolism and the progression of numerous types of cancer. Recent studies suggested that CD154 has anti-tumor activity and growth-inhibitory effects and that PTBP1 plays a crucial role in stabilizing CD154 mRNA (50). PTBP1 can reduce the expression of hypoxia-inducible factor 1α (HIF-1α) by modulating its mRNA stability, thereby inhibiting cell invasion when localized in the cytoplasm (51).
Recently, a study showed that PTBP1 induces the mRNA expression of p19 and promotes the proliferation of LUAD cells (52). Studies focusing on the function of PTBP1 in the modulation of RNA splicing in the nucleus was also found that it may play crucial oncogenic roles in the progression of various cancers. Thus, PTBP1 plays an important role and has different functions in tumorigenesis by regulating the amounts of target genes associated with malignancy.
Our data revealed that PTBP1 was significantly higher in LUAD cancer tissues compared with normal human lung tissue, consistent with previous studies (53). A recent study found that PTBP1 is overexpressed in ovarian tumors and colorectal cancer (54), indicating that PTBP1 is closely associated with the pathogenesis and development of cancer. However, the correlation of PTBP1 with clinical characteristics has not been clarified. Further analysis was performed to investigate the relationship between PTBP1 expression in LUAD tissues and clinicopathological characteristics of cancer. The results revealed that the level of PTBP1 expression in LUAD tissue was positively correlated with pathological stage and adverse clinical outcomes.
Regarding PTBP1, Morrel et al. suggested that PTBP1 might be a target of miR-214, which could reduce the endothelial cell glycolysis by inhibiting PTBP1 (55). Akao et al. found that PTBP1 is a target gene of microRNA-133b in colorectal tumors and that microRNA-133b might reduce the proliferation and invasion ability of COAD by inhibiting PTBP1 (56). In the present study, the PTBP1 expression significantly increased in the LUAD cells with overexpression of miR-195-5p upon and qPCR, while the PTBP1 expression significantly reduced in the A549 cells with inhibited expression of miR-195-5p. Via the dual-luciferase reporter assay, PTBP1 was confirmed to be the direct target gene of miR-195-5p, which could improve the cell proliferation and migration of LUAD cells. Additionally, our results suggested that miR-195-5p could have inhibited the cell proliferation and migration of LUAD cells and induced cell apoptosis. Moreover, it was also confirmed that the overexpression of PTBP1 might have promoted cell proliferation and migration in the A549 cells, while miR-195-5p might have inhibited cell proliferation and migration by reducing the PTBP1expression. We also found that PTBP1 expression was significantly correlated with the TMB and MSI in LUAD. PTBP1 expression was also positively or negatively correlated with diverse immune cell infiltration. Finally, our results showed that PTBP1 expression was negatively correlated with sensitivity to numerous drugs. The above findings offer promise for the diagnosis and treatment of lung cancer in the future.
This study improves our understanding of the correlation between miRNA-195-5p and LUAD, but some limitations still exist. First, although we explored the correlation between miRNA-195-5p and immune infiltration in LUAD patients, there is a lack of experiments to validate the function of miRNA-195-5p in the tumor microenvironment regulation of LUAD. Second, we uncover that depletion of miRNA-195-5p was inhibited cell proliferation and cell migration of LUAD cells.
However, the molecular mechanisms of miRNA-195-5p in tumor growth and metastasis need to be explored in further studies. Third, we did not conduct the in vivo experiments to validate the function of miRNA-195-5p in the tumor metastasis and tumor microenvironment regulation of LUAD. In the future, we will further study the function of miRNA-195-5p in tumor metastasis and tumor microenvironment regulation of LUAD.
Conclusion
In summary, our findings demonstrate that downregulation of miRNA-195-5p was associated with poor survival in patients with LUAD, and miRNA-195-5p inhibits growth and invasion of LUAD cells by regulating PTBP1 may provide a critical diagnostic and prognostic molecular marker for LUAD.
Funding
This work was supported by the National Nature Science Foundation of China (82160508), Yunnan Applied Basic Research Projects (YNWRMY-2019-067) Yunnan Province Specialized Training Grant for High-Level Healthcare Professionals (D-201614), and Yunnan Province Applied Basic Research Foundation (2019FE001) to LD.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
Ethics statement
This study was reviewed and approved by the Ethics Committee of The Third Affiliated Hospital of Kunming Medical University.
Author contributions
LD, JW, and DZ designed this work, and performed experiments, YY and LT analyzed data. YZ and XJ wrote and revised the manuscript. All authors have read and approved the final version of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.862564/full#supplementary-material
References
1
LiHChenSLiuJGuoXXiangXDongTet al. Long Non-Coding RNA PVT1-5 Promotes Cell Proliferation by Regulating miR-126/SLC7A5 Axis in Lung Cancer. Biochem Biophys Res Commun (2018) 495(3):2350–5. doi: 10.1016/j.bbrc.2017.12.114
2
WangXAdjeiAA. Lung Cancer and Metastasis: New Opportunities and Challenges. Cancer Metastasis Rev (2015) 34(2):169–71. doi: 10.1007/s10555-015-9562-4
3
LiangRLiXLiWZhuXLiC. DNA Methylation in Lung Cancer Patients: Opening a "Window of Life" Under Precision Medicine. BioMed Pharmacother (2021) 144:112202. doi: 10.1016/j.biopha.2021.112202
4
WangPZhouYRichardsAM. Effective Tools for RNA-Derived Therapeutics: siRNA Interference or miRNA Mimicry. Theranostics (2021) 11(18):8771–96. doi: 10.7150/thno.62642
5
Ghafouri-FardSShooreiHBranickiWTaheriM. Non-Coding RNA Profile in Lung Cancer. Exp Mol Pathol (2020) 114:104411. doi: 10.1016/j.yexmp.2020.104411
6
NadalEZhongJLinRMReddyNRamnathMBOrringerACet al. A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma. Clin Cancer Res (2014) 20(12):3107–17. doi: 10.1158/1078-0432.CCR-13-3348
7
DuLSchagemanJJSubausteMCSaberBHammondSMPrudkinLet al. miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1. Mol Cancer Res (2009) 7(8):1234–43. doi: 10.1158/1541-7786.MCR-08-0507
8
FattahiSNikbakhshNRanaeiMSabourDAkhavan-NiakiH. Association of Sonic Hedgehog Signaling Pathway Genes IHH, BOC, RAB23a and MIR195-5p, MIR509-3-5p, MIR6738-3p With Gastric Cancer Stage. Sci Rep (2021) 11(1):7471. doi: 10.1038/s41598-021-86946-0
9
LinXWangSSunMZhangCWeiCYangCet al. miR-195-5p/NOTCH2-Mediated EMT Modulates IL-4 Secretion in Colorectal Cancer to Affect M2-Like TAM Polarization. J Hematol Oncol (2019) 12(1):20. doi: 10.1186/s13045-019-0708-7
10
LiuXZhouYNingYEGuHTongYWangN. MiR-195-5p Inhibits Malignant Progression of Cervical Cancer by Targeting Yap1. Onco Targets Ther (2020) 13:931–44. doi: 10.2147/OTT.S227826
11
YangCDaiYPangSGuoXet al. Efficacy of Abiraterone Combined With Flutamide on Prostate Cancer Patients and its Effect on Serum miR-493-5p and miR-195-5p. Oncol Lett (2020) 20(2):1922–30. doi: 10.3892/ol.2020.11719
12
WuXXiaTCaoMZhangPShiGChenLet al. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Technol Cancer Res Treat (2019) 18:1533033819887962. doi: 10.1177/1533033819887962
13
NieHMuJWangJLiY. Mir−195−5p Regulates Multi−Drug Resistance of Gastric Cancer Cells via Targeting ZNF139. Oncol Rep (2018) 40(3):1370–8. doi: 10.3892/or.2018.6524
14
LiLFengTZhangWGaoSWangRLvWet al. MicroRNA Biomarker hsa-miR-195-5p for Detecting the Risk of Lung Cancer. Int J Genomics (2020) 2020:7415909. doi: 10.1155/2020/7415909
15
PattonJGMayerSATempstPNadal-GinardB. Characterization and Molecular Cloning of Polypyrimidine Tract-Binding Protein: A Component of a Complex Necessary for Pre-mRNA Splicing. Genes Dev (1991) 5(7):1237–51. doi: 10.1101/gad.5.7.1237
16
TaniguchiKUchiyamaKAkaoY. PTBP1-Targeting microRNAs Regulate Cancer-Specific Energy Metabolism Through the Modulation of PKM1/M2 Splicing. Cancer Sci (2021) 112(1):41–50. doi: 10.1111/cas.14694
17
BielliPPanzeriVLattanzioRMutascioSPieraccioliMVolpeEet al. The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Clin Cancer Res (2018) 24(21):5422–32. doi: 10.1158/1078-0432.CCR-17-3850
18
HeXArslanADHoTTYuanCStampferMRBeckWTet al. Involvement of Polypyrimidine Tract-Binding Protein (PTBP1) in Maintaining Breast Cancer Cell Growth and Malignant Properties. Oncogenesis (2014) 3(1):e84. doi: 10.1038/oncsis.2013.47
19
AuweterSDAllainFH. Structure-Function Relationships of the Polypyrimidine Tract Binding Protein. Cell Mol Life Sci (2008) 65(4):516–27. doi: 10.1007/s00018-007-7378-2
20
SongYTzimaEOchsKBassiliGTrusheimHLinderMet al. Evidence for an RNA Chaperone Function of Polypyrimidine Tract-Binding Protein in Picornavirus Translation. Rna (2005) 11(12):1809–24. doi: 10.1261/rna.7430405
21
LiTFanJWangBTraughNChenQLiuJSet al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res (2017) 77(21):e108–10. doi: 10.1158/0008-5472.CAN-17-0307
22
RuBWongCNTongYZhongJYZhongSSWWuWCet al. TISIDB: An Integrated Repository Portal for Tumor-Immune System Interactions. Bioinformatics (2019) 35(20):4200–2. doi: 10.1093/bioinformatics/btz210
23
YangWSoaresJGreningerPEdelmanEJLightfootHForbesSet al. Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells. Nucleic Acids Res (2013) 41(Database issue):D955–61. doi: 10.1093/nar/gks1111
24
BasuABodycombeNECheahJHPriceEVLiuKSchaeferGIet al. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules. Cell (2013) 154(5):1151–61. doi: 10.1016/j.cell.2013.08.003
25
AgarwalVBellGWNamJWBartelDP. Predicting Effective microRNA Target Sites in Mammalian mRNAs. Elife (2015) 4:e05005. doi: 10.7554/eLife.05005
26
ChenYWangX. miRDB: An Online Database for Prediction of Functional microRNA Targets. Nucleic Acids Res (2020) 48(D1):D127–d131. doi: 10.1093/nar/gkz757
27
LiJHLiuSZhouHQuLHYangJH. Starbase V2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and Protein-RNA Interaction Networks From Large-Scale CLIP-Seq Data. Nucleic Acids Res (2014) 42(Database issue):D92–7. doi: 10.1093/nar/gkt1248
28
YuGWangLGHanYHeQY. Clusterprofiler: An R Package for Comparing Biological Themes Among Gene Clusters. Omics (2012) 16(5):284–7. doi: 10.1089/omi.2011.0118
29
YuanYJiangXTangLWangJZhangDChoWCet al. FOXM1/lncRNA TYMSOS/miR-214-3p-Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma. Front Mol Biosci (2021) 8:785767. doi: 10.3389/fmolb.2021.785767
30
LiuLBaiXWangJTangXRWuDHDuSSet al. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. Clin Cancer Res (2019) 25(24):7413–23. doi: 10.1158/1078-0432.CCR-19-0558
31
LinAZhangJLuoP. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front Immunol (2020) 11:2039. doi: 10.3389/fimmu.2020.02039
32
ChaiLKangXJSunZZZengMFYuSRDingYet al. MiR-497-5p, miR-195-5p and miR-455-3p Function as Tumor Suppressors by Targeting hTERT in Melanoma A375 Cells. Cancer Manag Res (2018) 10:989–1003. doi: 10.2147/CMAR.S163335
33
WangTRenYLiuRMaJShiLZhangRet al. miR-195-5p Suppresses the Proliferation, Migration, and Invasion of Oral Squamous Cell Carcinoma by Targeting Trim14. BioMed Res Int (2017) 2017:7378148. doi: 10.1155/2017/7378148
34
LuoQZhangZDaiZBasnetSLiSXuBet al. Tumor-Suppressive microRNA-195-5p Regulates Cell Growth and Inhibits Cell Cycle by Targeting Cyclin Dependent Kinase 8 in Colon Cancer. Am J Transl Res (2016) 8(5):2088–96.
35
XuHHuYWZhaoJYHuXMLiSFWangYCet al. MicroRNA-195-5p Acts as an Anti-Oncogene by Targeting PHF19 in Hepatocellular Carcinoma. Oncol Rep (2015) 34(1):175–82. doi: 10.3892/or.2015.3957
36
ZhangWWangYZhuZZhengYSongB. Propofol Inhibits Proliferation, Migration and Invasion of Gastric Cancer Cells by Up-Regulating microRNA-195. Int J Biol Macromol (2018) 120(Pt A):975–84. doi: 10.1016/j.ijbiomac.2018.08.173
37
ZuoWZhangWXuFZhouJBaiW. Long non-Coding RNA LINC00485 Acts as a microRNA-195 Sponge to Regulate the Chemotherapy Sensitivity of Lung Adenocarcinoma Cells to Cisplatin by Regulating CHEK1. Cancer Cell Int (2019) 19:240. doi: 10.1186/s12935-019-0934-7
38
ZhengJXuTChenFZhangY. MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-Small Cell Lung Cancer by Directly Targeting Ciapin1. Pathol Oncol Res (2019) 25(3):1181–90. doi: 10.1007/s12253-018-0552-z
39
WangHSuiZLWuXXTangPZhangHDYuZTet al. Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene. Pharmgenomics Pers Med (2021) 14:497–508. doi: 10.2147/PGPM.S302755
40
WangLQinDShiHZhangYLiHLHanQ. MiR-195-5p Promotes Cardiomyocyte Hypertrophy by Targeting MFN2 and FBXW7. BioMed Res Int 2019 (2019) 2019:1580982. doi: 10.1155/2019/1580982
41
LongZWangY. miR-195-5p Suppresses Lung Cancer Cell Proliferation, Migration, and Invasion Via Foxk1. Technol Cancer Res Treat (2020) 19:1533033820922587. doi: 10.1177/1533033820922587
42
YangRXingLZhengXSunYWangXChenJet al. The circRNA Circagfg1 Acts as a Sponge of miR-195-5p to Promote Triple-Negative Breast Cancer Progression Through Regulating CCNE1 Expression. Mol Cancer (2019) 18(1):4. doi: 10.1186/s12943-018-0933-7
43
MashouriLYousefiHArefARAhadiAMMolaeiFAlahariSK. Exosomes: Composition, Biogenesis, and Mechanisms in Cancer Metastasis and Drug Resistance. Mol Cancer (2019) 18(1):75. doi: 10.1186/s12943-019-0991-5
44
AiLXuAXuJ. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol (2020) 1248:33–59. doi: 10.1007/978-981-15-3266-5_3
45
LeeSSCheahYK. The Interplay Between MicroRNAs and Cellular Components of Tumour Microenvironment (TME) on Non-Small-Cell Lung Cancer (NSCLC) Progression. J Immunol Res (2019) 2019:3046379. doi: 10.1155/2019/3046379
46
WangCNortonJTGhoshSKimJFushimiKWuJYet al. Polypyrimidine Tract-Binding Protein (PTB) Differentially Affects Malignancy in a Cell Line-Dependent Manner. J Biol Chem (2008) 283(29):20277–87. doi: 10.1074/jbc.M803682200
47
HeXPoolMDarcyKMLimSBAuerspergNCoonJSet al. Knockdown of Polypyrimidine Tract-Binding Protein Suppresses Ovarian Tumor Cell Growth and Invasiveness In Vitro. Oncogene (2007) 26(34):4961–8. doi: 10.1038/sj.onc.1210307
48
McCutcheonIEHentschelSJFullerGNJinWCoteGJ. Expression of the Splicing Regulator Polypyrimidine Tract-Binding Protein in Normal and Neoplastic Brain. Neuro Oncol (2004) 6(1):9–14. doi: 10.1215/S1152851703000279
49
JinWMcCutcheonIEFullerGNHuangESCoteGJ. Fibroblast Growth Factor Receptor-1 Alpha-Exon Exclusion and Polypyrimidine Tract-Binding Protein in Glioblastoma Multiforme Tumors. Cancer Res (2000) 60(5):1221–4.
50
HamiltonBJGeninACronRQRigbyWF. Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression. Mol Cell Biol (2003) 23(2):510–25. doi: 10.1128/MCB.23.2.510-525.2003
51
WangMJLinS. A Region Within the 5'-Untranslated Region of Hypoxia-Inducible Factor-1alpha mRNA Mediates its Turnover in Lung Adenocarcinoma Cells. J Biol Chem (2009) 284(52):36500–10. doi: 10.1074/jbc.M109.008904
52
LinSWangMJTsengKY. Polypyrimidine Tract-Binding Protein Induces P19(Ink4d) Expression and Inhibits the Proliferation of H1299 Cells. PloS One (2013) 8(3):e58227. doi: 10.1371/journal.pone.0058227
53
LiSShenLHuangLLeiSCaiXBreitzigMet al. PTBP1 Enhances Exon11a Skipping in Mena pre-mRNA to Promote Migration and Invasion in Lung Carcinoma Cells. Biochim Biophys Acta Gene Regul Mech (2019) 1862(8):858–69. doi: 10.1016/j.bbagrm.2019.04.006
54
LiXHanFLiuWShiX. PTBP1 Promotes Tumorigenesis by Regulating Apoptosis and Cell Cycle in Colon Cancer. Bull Cancer (2018) 105(12):1193–201. doi: 10.1016/j.bulcan.2018.08.013
55
CarusoPDunmoreBJSchlosserKSchoorsSDos SantosCPerez-IratxetaCet al. Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2. Circulation (2017) 136(25):2451–67. doi: 10.1161/CIRCULATIONAHA.117.028034
56
TaniguchiKSakaiMSugitoNKumazakiMShinoharaHYamadaNet al. PTBP1-Associated microRNA-1 and -133b Suppress the Warburg Effect in Colorectal Tumors. Oncotarget (2016) 7(14):18940–52. doi: 10.18632/oncotarget.8005
Summary
Keywords
LUAD, miRNA-195-5p, PTBP1, immune cell infiltration, drug sensitivity
Citation
Duan L, Wang J, Zhang D, Yuan Y, Tang L, Zhou Y and Jiang X (2022) Immune-Related miRNA-195-5p Inhibits the Progression of Lung Adenocarcinoma by Targeting Polypyrimidine Tract-Binding Protein 1. Front. Oncol. 12:862564. doi: 10.3389/fonc.2022.862564
Received
26 January 2022
Accepted
07 April 2022
Published
05 May 2022
Volume
12 - 2022
Edited by
Jun Zhang, University of Kansas Medical Center, United States
Reviewed by
Sohini Chakraborty, NYU Grossman School of Medicine, United States; Chen Li, Free University of Berlin, Germany
Updates
Copyright
© 2022 Duan, Wang, Zhang, Yuan, Tang, Zhou and Jiang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yongchun Zhou, chungui7625@163.com; Xiulin Jiang, jiangxiulin@mail.kiz.ac.cn
†These authors have contributed equally to this work
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.